Analysts Offer Predictions for CervoMed Q1 Earnings

CervoMed Inc. (NASDAQ:CRVO) – Brookline Capital Management raised their Q1 2025 earnings per share estimates for CervoMed in a report issued on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian now anticipates that the company will earn ($0.47) per share for the quarter, up from their previous forecast of ($0.48). Brookline Capital Management currently has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.75) EPS.

A number of other equities research analysts also recently issued reports on the company. Morgan Stanley reiterated an “underweight” rating on shares of CervoMed in a research report on Wednesday, December 11th. Roth Capital upgraded CervoMed to a “strong-buy” rating in a research report on Thursday, December 5th. Roth Mkm increased their price objective on CervoMed from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday. HC Wainwright downgraded CervoMed from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 17th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of CervoMed in a research report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, CervoMed has an average rating of “Moderate Buy” and a consensus price target of $27.50.

CervoMed Stock Performance

Shares of CRVO stock opened at $14.29 on Thursday. CervoMed has a 52-week low of $1.80 and a 52-week high of $25.92. The company has a market capitalization of $88.17 million, a PE ratio of -7.04 and a beta of 1.84. The business’s fifty day moving average is $3.30 and its 200 day moving average is $7.87.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The company had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $1.51 million. CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%.

Institutional Investors Weigh In On CervoMed

Large investors have recently added to or reduced their stakes in the company. Barclays PLC raised its position in CervoMed by 323.6% during the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after purchasing an additional 5,919 shares in the last quarter. Perigon Wealth Management LLC bought a new position in shares of CervoMed during the fourth quarter valued at about $147,000. State Street Corp grew its stake in shares of CervoMed by 28.1% during the third quarter. State Street Corp now owns 104,456 shares of the company’s stock valued at $1,525,000 after buying an additional 22,903 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of CervoMed by 13.9% during the third quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock valued at $1,678,000 after buying an additional 14,042 shares during the last quarter. Finally, Citizens Financial Group Inc. RI grew its stake in shares of CervoMed by 13.2% during the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock valued at $445,000 after buying an additional 3,553 shares during the last quarter. Hedge funds and other institutional investors own 25.15% of the company’s stock.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.